Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: comparison with postheparin plasma
Abstract
The catalytically inactive form of lipoprotein lipase (LPL) is detectable at high levels in serum, although its physiologic role remains unknown. The aim of this study was to elucidate the clinical significance of serum LPL compared with postheparin LPL or the net increment (Delta) of LPL (postheparin - preheparin LPL). We measured the LPL mass before and 15 minutes after the injection of heparin in 164 subjects with hyperlipidemia. LPL mass was measured by a sensitive sandwich enzyme-linked immunosorbent assay (ELISA). Serum LPL was one fifth of the postheparin LPL concentration. There was a weak correlation between the serum LPL and postheparin LPL concentrations (r =.225, P </=.005). The Delta LPL concentration was strongly related to the postheparin LPL concentration (r =.965, P </=.0001), but not to the preheparin LPL mass, suggesting that the weak correlation between serum LPL and postheparin LPL levels was attributable to contamination of postheparin plasma by pre-existing LPL (preheparin LPL). Both serum and postheparin LPL were significantly lower in diabetic patients and in subjects with high levels of triglyceride or low levels of high-density lipoprotein (HDL). Serum LPL was correlated negatively with triglyceride, remnants, and insulin resistance and was positively correlated with HDL cholesterol and low-density lipoprotein (LDL) size. Postheparin LPL was strongly correlated with HDL cholesterol, but not with other parameters, as was serum LPL. Delta LPL mass did not show a closer association with triglyceride metabolism than postheparin LPL or preheparin LPL. In conclusion, serum LPL measurement is simple and seems to be useful for studying triglyceride metabolism.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pre-heparin LPL concentration indicates the amount of systemic LPL activity.
“However, with several findings showing that pre-heparin LPL concentration indicate the amount of systemic LPL activity [64–66], Tanaka et al. turned the target to pre-heparin LPL, and found that 12 weeks of jogging training increased pre-heparin LPL concentrations in overweight men [67].”
From Effects of aerobic exercise on lipids and lipoproteins (2017) · cites this paper as [65]
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · see citing works
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,009 · see citing works
Identification of multiple subclasses of plasma low density lipoproteins in normal humans.
Krauss, R. M., & Burke, D. J. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38178-5 · Cited by 992 · see citing works
Lipolytic Enzymes and Plasma Lipoprotein Metabolism
Nilsson‐Ehle, P., Garfinkel, A. S., & Schotz, M. C. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.003315 · Cited by 754 · see citing works
Merkel, M., Eckel, R. H., & Goldberg, I. J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200015-jlr200 · Cited by 520 · see citing works
Nakajima, K., SAITO, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., Campos, E. M., et al. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90062-9 · Cited by 417 · see citing works
Kugiyama, K., Doi, H., Takazoe, K., Kawano, H., Soejima, H., Mizuno, Y., Tsunoda, R., Sakamoto, T., Nakano, T., Nakajima, K., et al. (1999) · Circulation · doi:10.1161/01.cir.99.22.2858 · Cited by 284 · see citing works
Triglyceride lpases and atherosclerosis
Olivecrona, G., & Olivecrona, T. (1995) · Current Opinion in Lipidology · doi:10.1097/00041433-199510000-00009 · Cited by 238 · see citing works
Ong, J. M., Kirchgessner, T. G., Schotz, M. C., & Kern, P. A. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37651-8 · Cited by 191 · see citing works
Tornvall, P., Olivecrona, G., Karpe, F., Hamsten, A., & Olivecrona, T. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.8.1086 · Cited by 172 · see citing works
Merkel, M., Kako, Y., Radner, H., Cho, I. S., Ramasamy, R., Brunzell, J. D., Goldberg, I. J., & Breslow, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13841 · Cited by 150 · see citing works
Vilella, E., Joven, J., Fernandez‐Borja, M., Vilaró, S., Brunzell, J., Olivecrona, T., & Bengtsson-Olivecrona, G. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36948-0 · Cited by 148 · see citing works
Lipoprotein lipase mass and activity in severe hypertriglyceridemia
Kobayashi, J., Hashimoto, H., Fukamachi, I., Tashiro, J., Shirai, K., Saito, Y., & Yoshida, S. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90144-s · Cited by 127 · see citing works
Watanabe, H., Miyashita, Y., Murano, T., Hiroh, Y., Itoh, Y., & Shirai, K. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00012-x · Cited by 69 · see citing works
The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum
Shirai, K., Itoh, Y., Sasaki, H., Totsuka, M., Murano, T., Watanabe, H., & Miyashita, Y. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00063-7 · Cited by 64 · see citing works
Miyashita, Y., Shirai, K., Itoh, Y., Sasaki, H., Totsuka, M., Murano, T., & Watanabe, H. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00369-2 · Cited by 62 · see citing works
Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis
Hitsumoto, T., Ohsawa, H., Uchi, T., Noike, H., Kanai, M., Yoshinuma, M., Miyashita, Y., Watanabe, H., & Shirai, K. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00413-5 · Cited by 61 · see citing works
Kern, P. A., Martin, R., Carty, J., Ij, G., & Ong, J. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42756-7 · Cited by 55 · see citing works
Sakaue, T., Hirano, T., Yoshino, G., Sakai, K., Takeuchi, H. T., & Adachi, M. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00200-x · Cited by 50 · see citing works
Self-citationDefective enzyme protein in lipoprotein lipase deficiency
Auwerx, J. H., Babirak, S. P., Fujimoto, W. Y., Iverius, P., & Brunzell, J. D. (1989) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1989.tb00255.x · Cited by 44 · see citing works
Enhancement of preheparin serum lipoprotein lipase mass by bezafbirate administration
Totsuka, M., Miyashita, Y., Ito, Y., Watanabe, H., Murano, T., & Shirai, K. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00394-4 · Cited by 43 · see citing works
Glaser, D., Yost, T. J., & Eckel, R. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41540-8 · Cited by 42 · see citing works
Watson, T. D. G., Tan, C., McConnell, M., Clegg, S. K., Squires, L. F., & Packard, C. J. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.3.405 · Cited by 32 · see citing works
Hitsumoto, T., Yoshinaga, K., Aoyagi, K., Sakurai, T., Kanai, M., Uchi, T., Noike, H., Ohsawa, H., Watanabe, H., & Shirai, K. (2002) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9.163 · Cited by 28 · see citing works
Saito, K., Sakurabayashi, I., & Manabe, M. (1998) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329803500605 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Effects of aerobic exercise on lipids and lipoproteins
Wang, Y., & Xu, D. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0515-5 · Cited by 436 · see citing works
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201 · see citing works
Lipoprotein Lipase S447X: A Naturally Occurring Gain-of-Function Mutation
Rip, J., Nierman, M. C., Ross, C. J., Jukema, J. W., Hayden, M. R., Kastelein, J. J. P., Stroes, E. S. G., & Kuivenhoven, J. A. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000219283.10832.43 · Cited by 157 · see citing works
Serum lipoprotein lipase mass: Clinical significance of its measurement
Kobayashi, J., Nohara, A., Kawashiri, M.-A., Inazu, A., Koizumi, J., Nakajima, K., & Mabuchi, H. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.12.003 · Cited by 35 · see citing works
Miyashita, M., Eto, M., Sasai, H., Tsujimoto, T., Nomata, Y., & Tanaka, K. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.2337 · Cited by 28 · see citing works
- Authors
- Hirano, T., Nishioka, F., & Murakami, T.
- Affiliations
- SHOWA Medical University (JP)
- Japan Nutrition University (JP)
- Corresponding author
- Hirano, Tsutomu
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 53
- Issue
- 4
- Pages
- 526-531
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2128490210
- Cited by
- 34
- References
- 26
- Citations by year
- 2025: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 1 · 2014: 2
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Keywords
- lipoprotein lipase, triglyceride metabolism, hyperlipidemia, heparin, HDL cholesterol, insulin resistance, triglyceride-rich lipoproteins, LDL particle size, diabetic patients, lipoprotein lipase activity
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Female, Heparin, Humans, Hyperlipidemias, Lipoprotein Lipase, Cholesterol, HDL, Male, Middle Aged, Triglycerides, Linear Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
